NCT04418167: JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

NCT04418167
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MAPK, MEK, RAS, RAF
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have a histologically or cytologically confirmed MAPK pathway mutation to be eligible, Breast cancer patients are only eligible for the dose escalation phase (not the expansion phase)
Exclusions: Patients with symptomatic central nervous system metastasis
https://ClinicalTrials.gov/show/NCT04418167

Comments are closed.

Up ↑